Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

FIRST BIO LAB, LLC

NPI: 1386315869 · IRVINE, CA 92614 · Clinical Medical Laboratory · NPI assigned 09/23/2021

$1.55M
Total Medicaid Paid
44,861
Total Claims
20,703
Beneficiaries
13
Codes Billed
2021-09
First Month
2024-11
Last Month

Provider Details

Authorized OfficialTORRES, ASHLIE (CEO)
NPI Enumeration Date09/23/2021

Related Entities

Other providers sharing the same authorized official: TORRES, ASHLIE

ProviderCityStateTotal Paid
AIM LABORATORIES LLC BRIDGETON MO $5.05M
FOCAL POINT LABORATORIES LLC MISSION VIEJO CA $253K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2021 722 $41K
2022 31,624 $1.02M
2023 9,857 $322K
2024 2,658 $173K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 15,432 7,065 $874K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 16,574 7,425 $237K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe 3,688 1,572 $157K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV 1,069 496 $111K
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B 1,066 603 $82K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 6,087 2,881 $66K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) 725 448 $22K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 45 45 $3K
K1034 Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count 116 111 $734.72
87811 Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) 14 12 $577.27
85025 Blood count; complete (CBC), automated, and automated differential WBC count 16 16 $17.69
80053 Comprehensive metabolic panel 15 15 $16.80
80061 Lipid panel 14 14 $11.54